Published in

Journal of Rheumatology, The Journal of Rheumatology, p. jrheum.201667, 2021

DOI: 10.3899/jrheum.201667

Links

Tools

Export citation

Search in Google Scholar

Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting

Journal article published in 2021 by Carmel Stober ORCID, Deepak R. Jadon ORCID, April W. Armstrong ORCID, Vinod Chandran ORCID, Maarten de Wit ORCID, Philip S. Helliwell ORCID, Philip Mease ORCID, Alexis Ogdie ORCID, Denis O’Sullivan, Stephen R. Pennington ORCID, Thorvardur Löve ORCID, Alberto Cauli ORCID, Leonieke van Mens ORCID, Robin Waxman, Jose U. Scher ORCID and other authors.
Distributing this paper is prohibited by the publisher
Distributing this paper is prohibited by the publisher

Full text: Unavailable

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

At the 2020 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)- Collaborative Research Network (CRN) annual meeting, the GRAPPA-CRN group presented a pilot investigator-initiated study protocol to test electronic case report forms (eCRFs) and proposed Standardized Operating Procedures (SOPs) to evaluate biomarkers of psoriatic arthritis (PsA) associated with axial disease. The progress on 3 studies was also presented: BioDAM PsA (Biomarkers as Predictors of structural DAMage in PsA; to validate soluble biomarkers as predictors of structural damage in PsA), PreventPsA (examining the development of PsA and risk factors among patients with psoriasis and no arthritis), and PredictORPsA (Predicting Treatment respOnse in patients with eaRly PsA; in collaboration with Pfizer using samples from the Oral Psoriatic Arthritis TriaL [OPAL], to identify biomarkers of treatment response). GRAPPA-CRN funding partnerships and applications are also underway with both the Innovative Medicines Initiative (IMI) in Europe and Accelerating Medicines Partnerships (AMP) 2.0 in the USA, and the progress of these applications and associated objectives were presented.